Menu Search
Equities

ProAssurance Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PRK:FRA

ProAssurance Corp

Actions
  • Price (EUR)20.60
  • Today's Change0.20 / 0.98%
  • Shares traded396.00
  • 1 Year change+49.28%
  • Beta0.0503
Data delayed at least 15 minutes, as of Feb 13 2026 14:46 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

ProAssurance Corporation is a specialty insurer with expertise in medical professional liability, products liability for medical technology and life sciences, legal professional liability, and workers' compensation insurance. The Company's segments include Specialty P&C, Workers' Compensation Insurance, Segregated Portfolio Cell Reinsurance and Corporate. The Specialty Property and Casualty (Specialty P&C) segment is focused on professional liability insurance and medical technology liability insurance. Professional liability insurance is offered to healthcare providers and institutions and, to a lesser extent, to attorneys and their firms. The Workers' Compensation Insurance segment offers workers' compensation products in approximately 19 states in the East, South and Midwest regions of the continental United States. The Segregated Portfolio Cell Reinsurance segment includes the results of SPCs at Inova Re and Eastern Re, the Company's Cayman Islands SPC operations.

  • Revenue in USD (TTM)1.10bn
  • Net income in USD33.71m
  • Incorporated2000
  • Employees1.04k
  • Location
    ProAssurance Corp100 Brookwood PlBIRMINGHAM 35209-6811United StatesUSA
  • Phone+1 (205) 877-4400
  • Fax+1 (205) 868-4073
  • Websitehttps://www.proassurance.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.